

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medlive Technology Co., Ltd.

醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

PROPOSED CHANGE OF AUDITOR

The board of directors (the “**Board**”) of Medlive Technology Co., Ltd. (the “**Company**”) announces the proposed retirement of the Company’s current auditor, Ernst & Young (“**EY**”), at the conclusion of the annual general meeting of the Company to be held on 15 May 2026 (the “**2026 AGM**”). This announcement is made by the Company pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

As the Company and EY were not able to reach consensus on the audit fee for the year ending 31 December 2026, the Company initiated a tender process for the role of external auditor in March 2026 and on 17 April 2026, the Board resolved, with the recommendation of the audit committee of the Company (the “**Audit Committee**”) to propose the appointment of Deloitte Touche Tohmatsu (“**Deloitte**”) as the new auditor of the Company to hold office from the conclusion of the 2026 AGM and until the conclusion of the next annual general meeting of the Company. Such proposed appointment is subject to the approval by the Shareholders at the 2026 AGM.

EY has confirmed that there are no matters in connection with its retirement as auditors of the Company that should be brought to the attention of shareholders of the Company (the “**Shareholders**”). The Board and the Audit Committee of the Company (the “**Audit Committee**”) have confirmed that there is no disagreement between the Company and EY and that there are no other matters or circumstances regarding the proposed change of auditor which should be brought to the attention of the Shareholders.

In reaching its recommendation to the Board, the Audit Committee has considered a number of factors, including but not limited to,

- (i) the audit proposal of Deloitte which includes the audit plan and timetable and the size and seniority of the audit team serving the Company;
- (ii) Deloitte's reputation in the market and resources;
- (iii) Deloitte's industry knowledge, experience and technical competence in handling audit works for companies listed on The Stock Exchange of Hong Kong Limited;
- (iv) the appropriateness of the audit fees proposed by Deloitte taking into account (a) its reputation, qualifications and experience; (b) the proposed work scope; (c) the size and seniority of the audit team serving the Company; (d) the Company's size, complexity and risk profile; and (e) Deloitte's committed partner participation in on-site work;
- (v) its independence from the Group and objectivity; and
- (vi) the relevant guidelines issued by the Accounting and Financial Reporting Council.

Having considered the above factors, the Audit Committee assessed and considered that Deloitte would be independent, competent and capable and suitable to act as the auditor of the Company, and the Audit Committee and the Board are of the view that the proposed appointment of Deloitte as the auditor of the Company is in the interest of the Company and the Shareholders as a whole, and recommend the Shareholders to vote in favour of the ordinary resolution regarding the proposed appointment at the 2026 AGM.

A circular containing, among other matters, the proposed appointment of auditor and a notice of the 2026 AGM together with the related form of proxy will be provided to the Shareholders as soon as practicable.

By order of the Board
Medlive Technology Co., Ltd.
Tian Liping
Chairwoman and Chief Executive Officer

Hong Kong, 17 April 2026

As at the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.